Jan Wald
Jan Wald
boston heard scientific single
I haven't heard from a single Guidant shareholder who doesn't like the Boston Scientific deal.
earnings interest investor renew report
There was nothing in the earnings report that would renew investor interest.
easily
I think they easily could go up to $76 without a lot of damage.
johnson stronger threat
The combination of Guidant and Johnson & Johnson is a stronger threat to Medtronic,
boston buying good insider investors scientific
I think investors do take insider buying as a good sign, and I think they especially wanted Boston Scientific to do it.
bent
It underscores why they were so bent on doing the Guidant deal.
hurting
I think of all the pieces, it's pharmaceuticals that are hurting them the most.
accept board boston clearing price scientific terms
The price wasn't as important as clearing up some terms and conditions. If Boston Scientific has done that, then I don't know why Guidant's board wouldn't accept this bid.